Drug
Relacorilant clinical trials
Also written CORT125134.
- studies test it
- 25
- open now
- 3
- in phase 3
- 4
- first study started
- 2014
Keep track of what changes. Save the relacorilant studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Brand
Development codes
Combined with it in one product
Studies by the year they started
25 studies that test it; most in 2018 (7)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2016 | 4 |
| 2017 | 1 |
| 2018 | 7 |
| 2019 | 1 |
| 2020 | 5 |
| 2021 | 1 |
| 2022 | 2 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 15
- Phase 2
- 7
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 22 · Other 3
Corcept Therapeutics (22) · University of Chicago (2) · ARCAGY/ GINECO GROUP (1)
Often tested with
Tested in the same studies.
Albumin-Bound Paclitaxel (6) · Paclitaxel (6) · Enzalutamide (1) · Pembrolizumab (1) · Itraconazole (1) · Prednisone (1) · Glucose (1) · Midazolam (1)
Studies
Open first, then newest update. How each study uses relacorilant is read from its arms, and is right about nine times in ten.
Testing it · 25
- Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic AdenocarcinomaRecruitingPhase 2Corcept TherapeuticsNCT07259317Written as Relacorilant
- A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate CancerRecruitingPhase 2University of ChicagoNCT05726292Written as Relacorilant
- Relacorilant and Nab-Paclitaxel in Recurrent or Metastatic Cervical CancerNot yet recruitingPhase 2ARCAGY/ GINECO GROUPNCT07763496Written as Relacorilant
- Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing SyndromeActive, not recruitingPhase 2Corcept TherapeuticsNCT03604198Written as relacorilant
- Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube CancerActive, not recruitingPhase 3Corcept TherapeuticsNCT05257408Written as Relacorilant 150 mg
- Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate CancerCompletedPhase 1University of ChicagoNCT03674814Written as Relacorilant
- Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedPhase 2Corcept TherapeuticsNCT03776812Written as Relacorilant
- A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal AdenomasCompletedPhase 3Corcept TherapeuticsNCT04308590Written as Relacorilant
- A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing SyndromeCompletedPhase 3Corcept TherapeuticsNCT03697109Written as Relacorilant
- Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)CompletedPhase 1Corcept TherapeuticsNCT04373265Written as Relacorilant
- Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal AdenocarcinomaTerminatedPhase 3Corcept TherapeuticsNCT04329949Written as Relacorilant, 100 mg and 25 mg
- A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of RelacorilantCompletedPhase 1Corcept TherapeuticsNCT06094725Written as Relacorilant
- A Study to Evaluate the Pharmacokinetics of the CORT125134 Phase 2 Formulation in Healthy Male SubjectsCompletedPhase 1Corcept TherapeuticsNCT06094712Written as CORT125134
- A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy SubjectsCompletedPhase 1Corcept TherapeuticsNCT06094738Written as Relacorilant under fasted conditions
- A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of CORT125134 in Healthy SubjectsCompletedPhase 1Corcept TherapeuticsNCT06094790Written as CORT125134 150 mg
- Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy ParticipantsCompletedPhase 1Corcept TherapeuticsNCT05347979Written as Relacorilant
- Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid TumorsCompletedPhase 1/2Corcept TherapeuticsNCT02762981Written as Relacorilant with nab-paclitaxel
- T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy VolunteersCompletedPhase 1Corcept TherapeuticsNCT04795479Written as Relacorilant
- Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and Its MetabolitesCompletedPhase 1Corcept TherapeuticsNCT03512548Written as Relacorilant 350mg
- Study to Evaluate CORT125134 in Participants With Cushing's SyndromeCompletedPhase 2Corcept TherapeuticsNCT02804750Written as CORT125134
See all 25 studies that test relacorilant →
Given in every arm · 1 — relacorilant is usual care beside what is tested
Codes
What other systems call relacorilant · ClinicalTrials.gg INT001143
- MeSH (NLM) C000633444relacorilantOne source NLM
- UNII (FDA) 2158753C7ERELACORILANTConfirmed FDA, NLM, Wikidata
- Wikidata Q48845466relacorilantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C127838RelacorilantOne source FDA
- DrugBank DB14976One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000633444 | relacorilant | One source NLM |
| UNII (FDA) | 2158753C7E | RELACORILANT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q48845466 | relacorilant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C127838 | Relacorilant | One source FDA |
| DrugBank | DB14976 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.